The Society For Biomaterials is excited to host the 2022 Annual Meeting at the Baltimore Marriott Waterfront, April 27-30, 2022. In keeping with the history of our host city, the theme for the SFB 2022 Annual Meeting is "The Perilous Fight to Translate Innovative Research to Commercial Viability". This year's program is focused on ideas that involve breakthroughs in biomaterials science, translation of basic research to clinical application, next-generation medical devices, and content that explores standards development, regulatory issues, and commercial realities.
We continue to closely monitor the coronavirus outbreak as the health, safety, and well-being of the SFB community is our highest priority. SFB will continue to actively assess the situation and distribute further information and updates from the U.S. Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO). Furthermore, we are tracking all COVID-19 travel restrictions issued by the U.S. Department of State.
To ensure the safest possible environment for conference participants, SFB will follow guidance regarding large gatherings from the CDC, WHO, and the Baltimore City Health Department. SFB will issue periodic updates as they become available.
2022 Annual Meeting Keynote Address and Panel Discussion
Dr. Cato T. Laurencin, MD, PhD
Our keynote speaker this year will be Cato T. Laurencin, MD, PhD who will speak on Diversity as a Driver for Innovation. Dr. Laurencin's address will be immediately followed by a panel discussion featuring additional members of the biomaterials community. It is well established that creating teams with a wide array of experiences, perspectives, and backgrounds is an essential component of successful innovation and development of new ideas. Diversity comes in many forms, including differences in identity, career stages, and scientific disciplines. Innovation in our field also requires balancing the concerns of industry, academia, and regulatory bodies. This panel will discuss the importance of building diverse and empowered teams for the effective translation of innovative research into clinical solutions.